Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2

Biochemical Journal

Volumn 450, Issue 3, 2013, Pages 583-593

  Maurer, Eva ^a   Gütschow, Michael ^a   Stirnberg, Marit ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Hepatocyte growth factor activator inhibitor type 2 (HAI 2); Hepcidin; Iron homoeostasis; Kunitz type serine protease inhibitor; Matriptase 2; Type II transmembrane serine protease

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR TYPE 2; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIPTASE 2; PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IRON DEFICIENCY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS;

ANTIMICROBIAL CATIONIC PEPTIDES; BIOMIMETICS; CELL HYPOXIA; GENE EXPRESSION REGULATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; IRON; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 84874616394     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121518     Document Type: Article

References (48)

1. Velasco, G., Cal, S., Quesada, V., Sanchez, L. M. and Lopez-Otin, C. (2002) Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J. Biol. Chem. 277, 37637-37646
2. Du, X., She, E., Gelbart, T., Truksa, J., Lee, P., Xia, Y., Khovananth, K., Mudd, S., Mann, N., Moresco, E. M. et al. (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320, 1088-1092
3. Finberg, K. E., Heeney, M. M., Campagna, D. R., Aydinok, Y., Pearson, H. A., Hartman, K. R., Mayo, M. M., Samuel, S. M., Strouse, J. J., Markianos, K. et al. (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat. Genet. 40, 569-571
4. Folgueras, A. R., de Lara, F. M., Pendas, A. M., Garabaya, C., Rodriguez, F., Astudillo, A., Bernal, T., Cabanillas, R., Lopez-Otin, C. and Velasco, G. (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112, 2539-2545
5. Maxson, J. E., Chen, J., Enns, C. A. and Zhang, A. S. (2010) Matriptase-2-and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. J. Biol. Chem. 285, 39021-39028
6. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J. and Camaschella, C. (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8, 502-511
7. Stirnberg, M., Maurer, E., Horstmeyer, A., Kolp, S., Frank, S., Bald, T., Arenz, K., Janzer, A., Prager, K., Wunderlich, P. et al. (2010) Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface. Biochem. J. 430, 87-95
8. Kawaguchi, T., Qin, L., Shimomura, T., Kondo, J., Matsumoto, K., Denda, K. and Kitamura, N. (1997) Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 27558-27564
9. Shimomura, T., Denda, K., Kitamura, A., Kawaguchi, T., Kito, M., Kondo, J., Kagaya, S., Qin, L., Takata, H., Miyazawa, K. and Kitamura, N. (1997) Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 6370-6376
10. Lin, C. Y., Anders, J., Johnson, M. and Dickson, R. B. (1999) Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 274, 18237-18242
11. Oberst, M. D., Chen, L. Y., Kiyomiya, K., Williams, C. A., Lee, M. S., Johnson, M. D., Dickson, R. B. and Lin, C. Y. (2005) HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am. J. Physiol. Cell Physiol. 289, C462-C470
12. Szabo, R., Hobson, J. P., List, K., Molinolo, A., Lin, C. Y. and Bugge, T. H. (2008) Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J. Biol. Chem. 283, 29495-29504
13. Kojima, K., Tsuzuki, S., Fushiki, T. and Inouye, K. (2008) Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J. Biol. Chem. 283, 2478-2487
14. Benaud, C., Dickson, R. B. and Lin, C. Y. (2001) Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268, 1439-1447
15. Miyake, Y., Tsuzuki, S., Yasumoto, M., Fushiki, T. and Inouye, K. (2009) Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells. Cytotechnology 60, 95-103
16. Wang, J. K., Lee, M. S., Tseng, I. C., Chou, F. P., Chen, Y. W., Fulton, A., Lee, H. S., Chen, C. J., Johnson, M. D. and Lin, C. Y. (2009) Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am. J. Physiol. Cell Physiol. 297, C459-C470
17. Friis, S., Godiksen, S., Bornholdt, J., Selzer-Plon, J., Rasmussen, H. B., Bugge, T. H., Lin, C. Y. and Vogel, L. K. (2011) Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase. J. Biol. Chem. 286, 5793-5802
18. Tsuzuki, S., Murai, N., Miyake, Y., Inouye, K., Hirayasu, H., Iwanaga, T. and Fushiki, T. (2005) Evidence for the occurrence of membrane-type serine protease 1/matriptase on the basolateral sides of enterocytes. Biochem. J. 388, 679-687
19. Lin, C. Y., Tseng, I. C., Chou, F. P., Su, S. F., Chen, Y. W., Johnson, M. D. and Dickson, R. B. (2008) Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front. Biosci. 13, 621-635
20. Beliveau, F., Brule, C., Desilets, A., Zimmerman, B., Laporte, S. A., Lavoie, C. L. and Leduc, R. (2011) Essential role of endocytosis of the type II transmembrane serine protease TMPRSS6 in regulating its functionality. J. Biol. Chem. 286, 29035-29043
21. Lakhal, S., Schodel, J., Townsend, A. R., Pugh, C. W., Ratcliffe, P. J. and Mole, D. R. (2011) Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J. Biol. Chem. 286, 4090-4097
22. Maurer, E., Gutschow, M. and Stirnberg, M. (2012) Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: identification of a hypoxia-responsive element in the TMPRSS6 promoter region. Biol. Chem. 393, 535-540
23. Graham, F. L., Smiley, J., Russell, W. C. and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74
24. Sisay, M. T., Steinmetzer, T., Stirnberg, M., Maurer, E., Hammami, M., Bajorath, J. and Gutschow, M. (2010) Identification of the first low-molecular-weight inhibitors of matriptase-2. J. Med. Chem. 53, 5523-5535
25. Evan, G. I., Lewis, G. K., Ramsay, G. and Bishop, J. M. (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5, 3610-3616
26. Meynard, D., Vaja, V., Sun, C. C., Corradini, E., Chen, S., Lopez-Otin, C., Grgurevic, L., Hong, C. C., Stirnberg, M., Gutschow, M. et al. (2011) Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood 118, 747-756
27. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y. and Poellinger, L. (1999) Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274, 6519-6525
28. Sutter, C. H., Laughner, E. and Semenza, G. L. (2000) Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. U.S.A. 97, 4748-4753
29. Tanimoto, K., Makino, Y., Pereira, T. and Poellinger, L. (2000) Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298-4309
30. Altamura, S., D'Alessio, F., Selle, B. and Muckenthaler, M. U. (2010) A novel TMPRSS6 mutation that prevents protease auto-activation causes IRIDA. Biochem. J. 431, 363-371
31. Farady, C. J. and Craik, C. S. (2010) Mechanisms of macromolecular protease inhibitors. ChemBioChem 11, 2341-2346
32. Tseng, I. C., Chou, F. P., Su, S. F., Oberst, M., Madayiputhiya, N., Lee, M. S., Wang, J. K., Sloane, D. E., Johnson, M. and Lin, C. Y. (2008) Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am. J. Physiol. Cell Physiol. 295, C423-C431
33. Parr, C. and Jiang, W. G. (2001) Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol. 19, 857-863
34. Parr, C., Sanders, A. J. and Jiang, W. G. (2010) Hepatocyte growth factor activation inhibitors: therapeutic potential in cancer. Anti-Cancer Agents Med. Chem. 10, 47-57
35. Parr, C., Watkins, G., Mansel, R. E. and Jiang, W. G. (2004) The hepatocyte growth factor regulatory factors in human breast cancer. Clin. Cancer Res. 10, 202-211
36. Muller-Pillasch, F., Wallrapp, C., Bartels, K., Varga, G., Friess, H., Buchler, M., Adler, G. and Gress, T. M. (1998) Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim. Biophys. Acta 1395, 88-95
37. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y. and Kitamura, N. (1993) Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 268, 10024-10028
38. Kataoka, H., Suganuma, T., Shimomura, T., Itoh, H., Kitamura, N., Nabeshima, K. and Koono, M. (1999) Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J. Histochem. Cytochem. 47, 673-682
39. Nagakawa, O., Yamagishi, T., Akashi, T., Nagaike, K. and Fuse, H. (2006) Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 66, 447-452
40. Watanabe, T., Sakata, Y., Matsubara, S., Yamagishi, T., Nagaike, K., Kuwata, T. and Suzuki, M. (2006) Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy. J. Obstet. Gynaecol. Res. 32, 10-14
41. Kiyomiya, K., Lee, M. S., Tseng, I. C., Zuo, H., Barndt, R. J., Johnson, M. D., Dickson, R. B. and Lin, C. Y. (2006) Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am. J. Physiol. Cell Physiol. 291, C40-C49
42. Lee, M. S., Kiyomiya, K., Benaud, C., Dickson, R. B. and Lin, C. Y. (2005) Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am. J. Physiol. Cell Physiol. 288, C932-C941
43. Kirchhofer, D., Peek, M., Li, W., Stamos, J., Eigenbrot, C., Kadkhodayan, S., Elliott, J. M., Corpuz, R. T., Lazarus, R. A. and Moran, P. (2003) Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J. Biol. Chem. 278, 36341-36349
44. Generali, D., Fox, S. B., Berruti, A., Moore, J. W., Brizzi, M. P., Patel, N., Allevi, G., Bonardi, S., Aguggini, S., Bersiga, A. et al. (2007) Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin. Cancer Res. 13, 550-558
45. Heinz-Erian, P., Muller, T., Krabichler, B., Schranz, M., Becker, C., Ruschendorf, F., Nurnberg, P., Rossier, B., Vujic, M., Booth, I. W. et al. (2009) Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am. J. Hum. Genet. 84, 188-196
46. Tsai, W. C., Sheu, L. F., Chao, Y. C., Chen, A., Chiang, H. and Jin, J. S. (2007) Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin. J. Physiol. 50, 225-231
47. Vogel, L. K., Saebo, M., Skjelbred, C. F., Abell, K., Pedersen, E. D., Vogel, U. and Kure, E. H. (2006) The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 6, 176
48. Parr, C. and Jiang, W. G. (2006) Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer 119, 1176-1183